Loading…

Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma

The combination of alpha-interferon and 13-cis-retinoic acid has shown significant activity against a number of human tumors. We conducted a phase II trial to test whether the combination would have a major response rate of 30% or more in patients with refractory, metastatic melanoma. Eleven patient...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1993-02, Vol.11 (1), p.39-43
Main Authors: KAPIL DHINGRA, PAPADOPOULOS, N, LIPPMAN, S, LOTAN, R, LEGHA, S. S
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The combination of alpha-interferon and 13-cis-retinoic acid has shown significant activity against a number of human tumors. We conducted a phase II trial to test whether the combination would have a major response rate of 30% or more in patients with refractory, metastatic melanoma. Eleven patients were treated on the study. Alpha-interferon was administered subcutaneously three times a week at a dose of 10 million U/m2 and 13-cis-retinoic acid was administered orally at a dose of 1 mg/kg/day. No patient achieved a partial or complete remission. The combination of alpha-interferon and 13-cis-retinoic acid is unlikely to have significantly higher therapeutic activity than alpha-interferon alone.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00873908